Elevance Health, Inc. (ELV)
| Market Cap | 90.03B -0.4% |
| Revenue (ttm) | 200.42B +9.4% |
| Net Income | 5.24B -11.4% |
| EPS | 23.52 -8.1% |
| Shares Out | 217.16M |
| PE Ratio | 17.67 |
| Forward PE | 15.83 |
| Dividend | $6.88 (1.66%) |
| Ex-Dividend Date | Jun 10, 2026 |
| Volume | 215,215 |
| Open | 411.55 |
| Previous Close | 415.53 |
| Day's Range | 410.50 - 417.34 |
| 52-Week Range | 273.71 - 417.20 |
| Beta | 0.68 |
| Analysts | Buy |
| Price Target | 411.29 (-0.79%) |
| Earnings Date | Jul 16, 2026 |
About ELV
Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, a... [Read more]
Financial Performance
In 2025, Elevance Health's revenue was $199.13 billion, an increase of 12.62% compared to the previous year's $176.81 billion. Earnings were $5.66 billion, a decrease of -5.32%.
Financial StatementsAnalyst Summary
According to 22 analysts, the average rating for ELV stock is "Buy." The 12-month stock price target is $411.29, which is a decrease of -0.79% from the latest price.
News
Elevance Health price target raised to $476 from $411 at JPMorgan
JPMorgan raised the firm’s price target on Elevance Health (ELV) to $476 from $411 and keeps an Overweight rating on the shares. The firm updated healthcare service models. Published first…
Elevance Health price target raised to $465 from $435 at Mizuho
Mizuho raised the firm’s price target on Elevance Health (ELV) to $465 from $435 and keeps an Outperform rating on the shares. The firm believes the managed care sector is…
Elevance Health price target raised to $404 from $352 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Elevance Health (ELV) to $404 from $352 and keeps an Equal Weight rating on the shares. Managed care stocks have been “grinding…
Elevance Health price target raised to $460 from $435 at BofA
BofA analyst Kevin Fischbeck raised the firm’s price target on Elevance Health (ELV) to $460 from $435 and keeps a Buy rating on the shares. Data points continue to trickle…
Elevance Health participates in a conference call with JPMorgan
Healthcare Services Analyst holds a conference call with management on June 2 at 1 pm hosted by JPMorgan.Webcast Link
Elevance Health price target raised to $450 from $375 at Truist
Truist analyst David MacDonald raised the firm’s price target on Elevance Health (ELV) to $450 from $375 and keeps a Buy rating on the shares as part of a broader…
CMS says Elevance avoids sanctions after corrective action plan progress
The Centers for Medicare & Medicaid Services notified Elevance Health (ELV) that the company has completed Step 2 of its corrective action plan related to potential Medicare Advantage enrollment sanct...
Elevance makes progress toward resolving MA sanctions, Wells Fargo says
Wells Fargo analyst Stephen Baxter says that based on a new Centers for Medicare & Medicaid Services document just posted, Elevance Health (ELV) appears to be making progress to resolve…
Elevance Health Expands Access to Digital Tools, Helping Bridge the Healthcare Digital Divide
INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health is advancing its commitment to improving healthcare access by addressing one of healthcare's most pressing challenges: the digital divide. Through innova...
Elevance Health price target raised to $480 from $408 at Barclays
Barclays analyst Andrew Mok raised the firm’s price target on Elevance Health (ELV) to $480 from $408 and keeps an Overweight rating on the shares. The firm believes the managed…
Elevance Health price target raised to $460 from $400 at UBS
UBS raised the firm’s price target on Elevance Health (ELV) to $460 from $400 and keeps a Buy rating on the shares. Managed care organizations broadly raised guidance after stronger-than-expected…
Elevance Health upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank upgraded Elevance Health (ELV) to Buy from Hold with a price target of $498, up from $363. The firm upgraded three managed care names citing a stabilizing managed…
Elevance Health price target raised to $435 from $385 at Mizuho
Mizuho raised the firm’s price target on Elevance Health (ELV) to $435 from $385 and keeps an Outperform rating on the shares. The firm views the Q1 reports in the…
Elevance Health upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank upgraded Elevance Health (ELV) to Buy from Hold with a price target of $498, up from $363.
Elevance Health added to ‘Tactical Outperform’ list at Evercore ISI
Evercore ISI is adding Elevance Health (ELV) to the firm’s “Tactical Outperform” list for Q2, telling investors that the company is poised for “significant upside EPS this year” if current…
Easing medical costs a positive for health insurers, but real test lies ahead, analysts say
U.S. health insurers' strong first-quarter results signaled more stable medical costs after prolonged pressure, but Wall Street analysts want to see another similar quarter before they are convinced.
Elevance Health Transcript: AGM 2026
The meeting covered strong financial growth, board updates, and strategic initiatives in efficiency, digital transformation, and value-based care. All board proposals passed, while a shareholder proposal on political contributions failed.
Health Insurers Performing Better But There's Potential Trouble Ahead
Health insurance companies including UnitedHealthcare, CVS Health's Aetna, Centene and Blue Cross and Blue Shield plans owned by Elevance Health are seeing lower costs from patients submitting claims.
Major health insurers show signs of recovery – but a key test looms
Solid first-quarter results from major insurers like UnitedHealth, Elevance, Cigna and Humana have helped lift investor sentiment, even as insurers continue to grapple with higher medical costs. But a...
Elevance Health Advances Efforts to Close Critical Gaps in Mental Health Care
INDIANAPOLIS--(BUSINESS WIRE)--Despite growing awareness, mental health concerns remain difficult to navigate and often lead to avoidable crises, costly emergency room visits, and long-term strain on ...
Elevance Health Names Best in Class Primary Care Practices in Care Provider Recognition Program
INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health, along with its affiliated health plans, today announced 45 distinguished medical practices and health systems to be honored in its annual Care Provider ...
Elevance Health's Affiliated Health Plans Deliver More Predictable, Lower Healthcare Costs for Small Businesses
INDIANAPOLIS--(BUSINESS WIRE)--As small businesses continue to face rising healthcare costs, Elevance Health's affiliated health plans are delivering solutions that help employers offer competitive be...
Elevance Health Earnings Call Transcript: Q1 2026
Q1 results exceeded expectations with strong EPS and revenue growth, driven by ACA seasonality, cost management, and non-recurring investment income. Full-year EPS guidance was raised, and strategic investments in AI and Carelon are supporting operational improvements and long-term growth.
Elevance Health Earnings release: Q1 2026
Elevance Health released its Q1 2026 earnings on April 22, 2026, summarizing the period's financial results.
Elevance Health Slides: Q1 2026
Elevance Health has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 22, 2026.